Overexpression of myeloid cell leukemia 1 protein (Mcl-1), an anti-apoptotic B-cell lymphoma 2 (Bcl-2) family member, contributes to chemotherapy resistance of tumors. The short half-life of Mcl-1 makes it an interesting target for therapeutic agents that negatively interfere with cellular protein biosynthesis, such as oncolytic viruses. Vesicular Stomatitis Virus (VSV) has been established as the oncolytic virus that efficiently disrupts de novo protein biosynthesis of infected cells. Here, we show that after VSV infection, Mcl-1 protein levels rapidly declined, whereas the expression of other members of the Bcl-2 family remained unchanged. Mcl-1 elimination was a consequence of proteasomal degradation, as overexpression of a degradation-resistant Mcl-1 mutant restored Mcl-1 levels. Mcl-1 rescue inhibited apoptosis and thereby confirmed that Mcl-1 downregulation contributes to VSV-induced apoptosis. In vitro, VSV virotherapy in combination with chemotherapy revealed an enhanced therapeutic effect compared with the single treatments, which could be reverted by Mcl-1 rescue or RNA interference (RNAi)-mediated knockdown of pro-apoptotic Bax and Bak proteins. Finally, in a tumor mouse model, combinations of doxorubicin and VSV showed a superior therapeutic efficacy compared with VSV or doxorubicin alone. In summary, our data indicate that VSV virotherapy is an attractive strategy to overcome tumor resistance against conventional chemotherapy by elimination of Mcl-1.
Introduction
The Rhabdovirus family member Vesicular Stomatitis Virus (VSV) is a small enveloped, negative-sense singlestranded RNA virus that has recently been developed as an oncolytic agent for treating human cancers. VSV is one of the most attractive candidates for oncolytic virotherapy as its tropism allows infection of a wide variety of cancer cells, and its rapid and productive replication cycle confers a strong oncolytic potency. 1 Furthermore, replication of VSV is limited to cancer tissue as these cells usually accumulate aberrations in innate immunity pathways during transformation. In the case of VSV, an inactive interferon (IFN) response pathway resulting in reduced activation of key IFN-inducible genes seems to represent a major factor in cancer cell selectivity. In addition, tumors with mutations in the tumor suppressor p53, or activated Myc-or Ras-signaling were reported to be susceptible to VSV-mediated oncolysis. 2 Furthermore, tumor-specific alterations in translational control involving the rate-limiting cofactor eIF2B have been discussed to allow effective replication in tumor cells. [3] [4] [5] Although encoding for not more than five proteins, VSV massively manipulates the host cell. After infection, the matrix protein of VSV (VSV-M) is involved in disorganizing the cytoskeleton 6 and impairs antigen presentation. 7 To escape the host cell's antiviral mechanisms, VSV prevents protein biosynthesis of host proteins on different levels. VSV-M not only inhibits RNA polymerases I-III, 8, 9 but also blocks the nuclear-cytoplasmic export of host cell mRNAs by interaction with the RNA export proteins, Nup98 and Rae1. [10] [11] [12] [13] [14] In addition, the dephosphorylation of the eukaryotic translation initiation factor, eIF4E, averts the translation of host mRNAs. 15 Consequently, the host cell's protein biosynthesis machinery is efficiently shut down to inhibit the production of host antiviral proteins, whereas the production of viral proteins is facilitated. A response of infected host cells that has been reported is a general translation stop mediated by eIF2alpha phosphorylation to suppress translation of viral mRNAs. 16 The mitochondria-mediated apoptotic cascade (intrinsic pathway) is tightly regulated by B-cell lymphoma 2 (Bcl-2) family members. 17 Within the group of the prosurvival proteins (Bcl-2, Bcl-XL, Bcl-w, A1 and myeloid cell leukemia 1 protein (Mcl-1)), Mcl-1 represents an unconventional member with regard to structural and functional properties. It is a very short-lived protein that underlies a rapid turnover because of regulation on both mRNA and protein levels. 18 Downregulation of Mcl-1 does not directly initiate the apoptotic cell death pathway, but strongly facilitates induction of apoptosis by other external stimuli or cell stress. In human tumors, Mcl-1 is frequently overexpressed accompanied by resistance to conventional chemotherapeutic therapies. 18 For this reason, several studies focused on decreasing cellular Mcl-1 protein levels applying different approaches, for example, small molecule inhibitors or RNA interference (RNAi). 19, 20 Recently, it has been reported that the E1A protein of human Adenovirus type 5 is capable of downregulating protein levels of Mcl-1 21 followed by induction of apoptosis. Additionally, we showed that this decrease can be therapeutically exploited by combined virochemotherapy, 22 indicating that virus-induced Mcl-1 degradation is a promising tool to support conventional chemotherapy.
Therefore, our study aimed to analyze VSV-induced apoptosis by investigating the influence of VSV on Bcl-2 family members. In infected cancer cells, VSV induces apoptosis accompanied by autophagy as shown by strong activation of caspase-3 and cleavage of LC3. Although protein levels of other members of the Bcl-2 family remained constant, we observed a rapid elimination of Mcl-1 expression after VSV infection. Ectopic rescue of Mcl-1 significantly inhibited VSV-induced apoptosis, but did not interfere with VSV-mediated autophagy, thereby showing that proteasomal elimination of Mcl-1 specifically renders cells sensitive to VSVinduced apoptosis. Beyond that, we provide strong evidence that this antiviral switch can be successfully exploited for enhanced anti-tumor treatment in combination with conventional chemotherapy in vitro and in vivo. VSV-mediated downregulation of Mcl-1 sensitized the tumor cells for chemotherapy-induced apoptosis, which was dependent on the pro-apoptotic Mcl-1-binding partners, Bak and Bax. Whereas VSV virotherapy alone was only capable of reducing tumor growth, VSVvirochemotherapy resulted in complete inhibition of tumor growth and vast destruction of the tumors in vivo.
Results

Rapid proteasomal elimination of Mcl-1 induced by VSV infection contributes to VSV-induced apoptosis, but not to VSV-induced autophagy
In contrast to necrosis, cell death by apoptosis or autophagy is regulated by defined molecular pathways. Viral infections trigger specific intracellular defense mechanisms, which are often linked to innate and adaptive immune responses of the host. To identify molecular mechanisms involved in VSV-induced cell death, we investigated the expression of a subset of proteins involved in the execution of apoptosis through the intrinsic arm after VSV infection in p53 wild-type (wt) (HepG2 and A549) and p53-mutated (Huh-7) tumor cell lines. In these analyses, we focused on p53 as a crucial inductor of intrinsic apoptosis and of members of the Bcl-2 family, which maintain the integrity of the mitochondrial membrane. As shown in Figure 1a , expression of p53, Bcl-XL, Bcl-2, Bax, Bak, Bid and Bim remained constant during the time course after VSV infection. In contrast, we observed a rapid and specific elimination of Mcl-1 within 6-8 h after VSV infection in all tumor cells investigated (with higher multiplicity of infections Mcl-1 levels drop even faster, data not shown). Elimination of Mcl-1 was followed by a strong upregulation of caspase-3 activity, suggesting that downregulation of Mcl-1 plays an important role in the induction of apoptosis in VSV-infected cells (Figure 1b) .
Mcl-1 protein expression can be regulated by transcriptional and post-transcriptional mechanisms, but the rapid decline of Mcl-1 levels immediately starting after VSV infection strongly suggests that post-transcriptional mechanisms are responsible for this observation. At posttranslational level, it is well known that Mcl-1 can be degraded by several proteasome-dependent pathways, but it has also been shown that activated caspases are able to cleave Mcl-1 into apoptosis-promoting breakdown fragments. [23] [24] [25] [26] To identify the mechanism that is involved in VSV-mediated downregulation of Mcl-1, we treated VSV-infected cells with the pan-caspase inhibitor, z-VAD-fmk, and the proteasome inhibitor, MG132. Although caspase inhibition had no effect on the elimination of Mcl-1, application of MG132 completely prevented the elimination of Mcl-1, thus showing that proteasomal degradation is responsible for VSVmediated downregulation of Mcl-1 ( Figure 1c) .
VSV efficiently abrogates host cell protein biosynthesis by preventing matured cellular mRNAs to be transferred from the nucleus to the cytoplasm. We hypothesized that the inhibition of the de novo protein biosynthesis under normal protein turnover conditions is responsible for declining Mcl-1 protein levels in VSV-infected human cancer cells. We therefore disrupted the protein biosynthesis of human cancer cells applying low concentrations of the transcription inhibitor, Actinomycin D (1 mM), and monitored the effect on Mcl-1 protein levels. In A549 cells, Actinomycin D treatment resulted in a rapid elimination of Mcl-1 that resembles the elimination mediated by VSV (Figure 1d , comparable results were obtained for Huh-7, data not shown). Thus, block of cellular protein biosynthesis by the action of the VSV-M protein and proceeding degradation of proteins by the ubiquitin/proteasome machinery might represent the underlying mechanisms for Mcl-1 elimination in wt-VSV-infected cells. To further explore the specific contribution of VSV-M, we examined the effect of the VSV-M mutant virus, AV1, on Mcl-1 protein levels. As this virus has a limited capability to disrupt host cell protein biosynthesis, a prolonged Mcl-1 expression compared with wt-VSV is expected. In accordance with this hypothesis, human cancer cells infected with AV1 failed to eliminate Mcl-1 protein as efficiently as wt-VSV (Figure 1e ). In summary, we showed that VSV infection leads to a rapid decline of the anti-apoptotic Mcl-1 protein in human cancer cells. Our data support the hypothesis that this elimination is explained by inhibition of host cell protein expression through the viral matrix protein, and a normally proceeding protein degradation process by the proteasomes.
In contrast to apoptosis, autophagy is a cellular degradation program that can promote both cell death and survival. It has been shown that members of the Bcl-2 family can interact with the autophagy inducer, Beclin-1, mediating a crosstalk between autophagy and apoptosis. To investigate whether induction of autophagy, besides apoptosis, is also involved in VSV-induced cell death, we investigated tumor cells retrovirally transduced with an YFP-LC3 fusion protein to allow the Figure 4a ), thus confirming that VSV-mediated proteasomal elimination of Mcl-1 decisively contributes to caspase-3 activity induced by virochemotherapy. In addition to the investigation of apoptosis by caspase-3 assays, we carried out experiments to determine the overall cell killing of the combination treatment compared with the single treatments. Cells treated with doxorubicin, VSV or a combination of both were analyzed by flow cytometry analysis (propidium iodide staining) to determine the proportion of dead cells (Figure 4b ). In agreement with our other experiments, doxorubicin alone did not result in a marked increase of cell death. In contrast, the amount of dead cells increased sharply on infection with VSV and could be further elevated by simultaneous VSV and doxorubicin application, which is in concordance with the results of caspase-3 activation assays. Enhanced cell death due to doxorubicin treatment of VSV-infected cells could be observed in all investigated cell lines and could be further confirmed by trypan blue exclusion assay (data not shown).
As infection of human cells by the VSV-mutant, AV1, did not result in a rapid clearance of Mcl-1 from infected human cancer cells (Figure 1e ), we hypothesized that the prolonged presence of Mcl-1 should reduce the sensitizing effect of viral infection on chemotherapy-induced apoptosis. HepG2, A549 and Huh-7 cells were infected with a low multiplicity of infection of AV1 and analyzed for activation of caspase-3 24 h post-infection. Although AV1 infection induced apoptosis as depicted in Figure 4c , simultaneous application of doxorubicin was not capable of additionally increasing caspase-3 activity levels. This contrast to wt-VSV further supports the hypothesis that wt-VSV infection enhances the sensitivity for doxorubicin-induced apoptosis by eliminating anti-apoptotic Mcl-1 protein from the infected cells.
Mcl-1 protein, in concert with its pro-apoptotic binding partners, Bak and Bax, regulates the permeability of the mitochondrial outer membrane. The involvement of Bax and Bak in VSV-mediated apoptosis and chemotherapyinduced caspase-3 activation was further analyzed in Huh-7 cells transduced by retroviral vectors expressing short hairpin RNA directed against Bax or Bak (Figure 4d ). In agreement with the other results, silencing of Bak or Bax by RNAi resulted in a significantly reduced VSV-mediated caspase-3 activation and led to an impaired sensitization of the virally infected tumor cells against chemotherapy (Figures 4d and e) .
The increased extent of apoptosis induced by virochemotherapy in comparison with virotherapy alone strongly suggests a potential therapeutic cooperation between VSV virotherapy and chemotherapy, but a further important precondition for an effective virochemotherapy is the unimpaired viral replication during chemotherapy. The outcome of VSV virotherapy depends on a complex balance between VSV replication and tumor cytotoxicity. If infected tumor cells die prematurely with regard to viral progeny, this can impair therapeutic efficacy, as an optimized progress of production, release and spread of viral vectors may be prevented. We therefore assessed the effect of chemotherapy on VSV replication in different tumor cells. In terestingly, though VSV sensitized tumor cells to chemotherapy-mediated apoptosis, therapeutic concentrations of doxorubicin did not significantly disturb quantitative production of infectious VSV particles in HepG2, A549 or Huh-7 cells (Figure 5 ), indicating that chemotherapy does not impair VSV virotherapy.
We therefore investigated next whether the enhanced apoptosis of VSV-infected tumor cells due to chemotherapy results in improved efficacy of virochemotherapy compared with virotherapy alone in an animal tumor 
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P Schache et al model in vivo. To this end, A549-derived subcutaneous tumor xenografts were established on nude mice. Then, the tumor xenografts were intratumorally infected with VSV. Subgroups of mice were subjected to intravenous application of doxorubicin twice a week, or a combination of VSV virotherapy and doxorubicin treatments. In agreement with the results obtained from the in vitro experiments, treatment of A549 tumors with doxorubicin resulted in negligible therapeutic effects on tumor growth (Figure 6a ). In contrast, VSV virotherapy
Elimination of Mcl-1 in oncolytic virochemotherapy P Schache et al significantly reduced tumor growth. After treatment with systemic doxorubicin chemotherapy in combination with VSV virotherapy, enhanced therapeutic effects could be observed in vivo leading to complete inhibition of tumor growth ( Figure 6a ). As a rapidly growing xenograft model in nude mice was used in our in vivo experiments, ineffective removal of apoptotic cells can lead to underestimation of the true therapeutic efficacy of virochemotherapy when the tumor growth curves are compared. Therefore, hematoxylin/eosin and TUNEL (terminal deoxynucleotidyl transferase dUTP nick end labeling) stainings were carried out on sections obtained from paraffin embedded tumor xenografts after defined treatments. As expected from the study of tumor growth curves, sections obtained from the group that received only doxorubicin chemotherapy revealed solid tumor architecture without evidence of significant tumor destruction (Figure 6b ). In contrast, tumors treated with VSV alone showed areas of tumor destruction indicated by loss of cell nuclei and cell-cell adhesion (Figure 6b) , and enhanced tumor cell apoptosis distributed throughout the tumor mass ( Figure  6d ). However, in animals receiving the combination of systemic chemotherapy and VSV virotherapy, the therapeutic effect was strongly enhanced resulting in vast destruction of the tumor xenografts accompanied by strongly enhanced apoptosis (Figures 6b-d) .
It has been suggested that enhanced apoptosis of tumor cells could support intratumoral spreading of viral particles. Thus, we were interested in finding out whether intratumoral spreading of VSV was enhanced because of systemic chemotherapy. To visualize the ongoing viral replication, expression of VSV-G protein was investigated in immunostained paraffin sections. VSV-G staining in the tumors of mice receiving VSV virotherapy showed active viral replication 3 days after the last injection. However, both groups of virotherapy and combined virochemotherapy showed a comparable amount of VSV-G-expressing tumor cells, indicating that the enhanced effect of virochemotherapy is not mediated by an improved intratumoral spreading of VSV ( Figure  6c ). As tumors often harbor larger areas of dead cells, we verified that the areas of apoptotic cells are virally transduced to a large extent (Figure 6e ). It should be noted that proper VSV-G staining was applicable mainly to cells that were detected in an early phase of viral infection. In summary, an improved therapeutic effect of combined virochemotherapy (wt-VSV, doxorubicin) over single treatments due to enhanced apoptosis of tumor cells was observed in vivo, which confirms our in vitro data described above.
Discussion
In our study, we investigated molecular mechanisms involved in VSV-mediated cell death and potential enhancement of conventional chemotherapy by VSV virotherapy. After cell infection, cytopathic viruses elicit specific antiviral responses that drive the affected cell into a programmed cell death of apoptotic or autophagic phenotype, or even both. Though, the mitochondrial apoptotic pathway is more important in case of wt-VSV, VSV-M mutants seem to induce cell death predominantly through the extrinsic apoptotic pathway mediated by Fas and Daxx. [27] [28] [29] On the basis of the findings of this study, we show here that wt-VSV, but not the matrix protein mutated virus, AV1, is capable of rapidly eliminating Mcl-1 as an important anti-apoptotic element of the intrinsic apoptotic pathway from the infected cells.
In addition to VSV-mediated apoptosis of tumor cells, it has been shown that VSV induces autophagy in plasmacytoid dendritic cells, which is required for tolllike receptor-7 recognition and IFN-g production. 30 Intracellular events after virus entry and infection are usually tightly linked to the innate and adaptive immune response of the host not only in antigen-presenting cells, but also in normal tissue and tumor cells. Recently, it has been shown that Bax is required for IFN regulatory factor 3 phosphorylation and activation after VSV infection. 31 IFN regulatory factor 3 is in turn involved in p53-independent transactivation of the Mcl-1 antagonist, NOXA, 32 suggesting that common components are involved in VSV-induced apoptosis and IFN-activation pathways.
Mcl-1 protein is an unconventional member of the Bcl-2 family. It is equipped with an extremely short halflife, as it is subject to a rapid turnover through ubiquitin- Figure 5 Combination of vesicular stomatitis virus (VSV) and chemotherapy does not inhibit VSV production. Doxorubicin (100 ng/ml) was applied to HepG2, A549 and Huh-7 cells that subsequently were infected with VSV (multiplicity of infection (MOI) ¼ 0.1). Production of infectious viral particles within intervals of 12 h (under restoration of chemotherapeutic conditions) was analyzed by TCID 50 assay. Analysis of VSV titers did not reveal any statistically significant differences between the cells treated with or without doxorubicin. were subjected to TUNEL-and VSV-G-staining (with corresponding isotype control) as described above to match VSVinfection with apoptotic areas. A full colour version of this figure is available at the Gene Therapy journal online.
Elimination of Mcl-1 in oncolytic virochemotherapy P Schache et al the time course of VSV infection significantly reduced VSV-mediated apoptosis, but not VSV-induced autophagy. This was an unexpected finding as it has been shown that the Bcl-2 family members, Bcl-2 and Bcl-XL, can inhibit autophagy by binding the autophagy-mediator, Beclin-1. 34, 35 Our observation that Mcl-1 is not involved in the regulation of autophagy during VSV-infection may be explained by the significant weaker affinity of Mcl-1 to Beclin-1 compared with Bcl-2 or Bcl-XL. 36 We recently showed that downregulation of Mcl-1 after adenovirus infection sensitizes chemotherapyresistant hepatocellular carcinomas against chemotherapy. 22 A comparable downregulation of Mcl-1 after VSV infection suggests a general mechanism of viral-induced cell death. It has been shown that expression of the adenoviral E1A protein provokes a DNA damage response, 21 which may explain Mcl-1 elimination by oncolytic adenoviruses. As a consequence of our study, we cannot exclude that a yet unknown, active mechanism contributes to VSV-mediated Mcl-1 elimination.
However, it seems obvious that rapid turnover of Mcl-1 through ubiquitin-dependent protein degradation provides a very simple and effective mechanism to sensitize virally infected cells against intrinsic and extrinsic apoptotic stimuli. Infected cells could react in an impressively simple fashion by such a mechanism to hijacking of the host transcriptor and/or translation machinery by a parasite virus. Supporting the assumption that the rapid Mcl-1 degradation might exclusively be based on the short half-life and the blockage of de novo synthesis of Mcl-1 protein only, Actinomycin D-blocked transcription led to the elimination of Mcl-1 expression with comparable kinetics to that of VSV infection. Even more important, we and others provided evidence that a VSV mutant (VSV-AV1), which is attenuated in blocking host protein biosynthesis, was incapable of decreasing protein levels of Mcl-1 in human cancer cells of different origin (HepG2, A549, Huh-7 ( Figure 1e ) and the human B-lymphoma cell line, Karpas-422 37 ). 
Any mechanism that inhibits the pro-survival function of Mcl-1 should be able to sensitize chemotherapyresistant cancer cells to apoptosis. In agreement with this hypothesis, we showed that VSV virotherapy sensitized a variety of chemotherapy-resistant tumor cells for chemotherapy-apoptosis in a similar extent as it was reported earlier for oncolytic adenovirus virotherapy. Expression of an ubiquitination-resistant Mcl-1 protein or knockdown of the anti-apoptotic Mcl-1-binding partners, Bax and Bak, by short hairpin RNA abrogated the VSV-mediated sensitizing against chemotherapy, confirming that the elimination of Mcl-1 is sufficient to explain the enhanced effects observed between virotherapy and chemotherapy. Accordingly, prolonged Mcl-1 expression in the context of viral infection by using AV1 instead of wt-VSV did abolish the sensitizing effect of viral infection on doxorubicin-induced apoptosois.
As altered VSV replication in tumor cells by chemotherapy might also explain the enhanced effects of virochemotherapy, we investigated the effect of chemotherapy on VSV replication in cell culture experiments, and on viral infection and intratumoral viral spreading in vivo. We did not find any evidence in our experiments that the progeny and the distribution of the virotherapeutic vector was directly affected or impaired by chemotherapy.
In accordance with our in vitro results, VSV induced tumor cell apoptosis in an intensified manner in combination with systemic chemotherapy in vivo. The improved therapeutic effect of combined virochemotherapy compared with virotherapy alone is, in particular, evident after histological examination of the treated tumors. Although VSV virotherapy alone resulted only in inhibition of tumor growth with partially intact tumor histology, VSV virochemotherapy resulted in strongly enhanced apoptosis and vast destruction of the tumors. Importantly, enhanced cell killing, as observed in vitro for combination treatment (Figure 4b ), still allows production of sufficient viral progeny to unfold a superior therapeutic effect ( Figure 5) .
In our study, we show a strongly enhancing effect of VSV virotherapy with chemotherapy. This enhancement is explained by a selective, rapid and effective downregulation of Mcl-1 expression after VSV-infection, which renders tumor cells sensitive to chemotherapy-induced apoptosis. Consequently, virochemotherapy using VSV with wt M-protein should be an attractive strategy to improve therapeutic results in chemoresistant tumors.
Materials and methods
Cell lines and plasmids
The human cell lines A549 (lung adenocarcimona), HepG2 (Hepatocarcinoma) and Huh-7 (Hepatoma) were obtained from ATCC (Manassas, VA, USA). Cells were maintained in growth medium (DMEM+Glutamax, Life Technologies Inc., Gaithersburg, MD, USA) supplemented with 10% fetal bovine serum (Life Technologies), 100 U ml À1 penicillin and 100 mg ml 
Virus propagation and titering
Wild type VSV (Indiana serotype) was kindly provided by Mahtab Nourbakhsh (Medical School, Hannover, Germany). The VSV-mutant, AV1, was obtained from Oliver Ebert (TU, Munich, Germany). Viruses were expanded in BSR T7/5 cells. The viral titer of resulting supernatants was determined by viral plaquing and TCID 50 assay using BSR T7/5 cells. Viral titers (pfu ml À1 ) indicated in the figures are the results of three independent measurements. Human wt Adenovirus serotype 5 was propagated in A549 cells, purified by CsCl density gradient centrifugation according to standard protocols and titered by Rapid Titer Assay (Takara/Clontech) following the manufacturer's protocol.
Cell infection, chemotherapeutic treatment and western blot analysis
Cells grown to sub-confluency in 6 cm dishes were infected by VSV and/or treated by chemotherapeutic agents, as indicated in the figure legends. Chemotherapeutic reagents 5 0 -fluorouracil and doxorubicin were obtained from the Central Pharmacy at Medical School Hannover. The pan-caspase inhibitor, z-VAD-fmk, and the proteasome inhibitor, MG132, were purchased from Calbiochem, the transcription inhibitor Actinomycin D from Applichem (Darmstadt, Germany). At indicated points of time after treatment, cells were harvested and lysed using RIPA-buffer (1% NP-40, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate, 0.02% protease inhibitor cocktail (Sigma, Hamburg, Germany) in phosphate-buffered saline (PBS)). The cell debris was pelleted in a tabletop centrifuge and the supernatant was retained as a whole-cell extract. The protein concentration was determined by Bio-Rad protein assay (Bio-Rad, Richmond, CA, USA). 10-100 mg proteins were separated by 10-12.5% sodium dodecyl sulfate polyacrylamide gel electrophoresis and transferred onto a HyBond Nmembrane (Millipore, Eschborn, Germany). Extract quality and equal loading were confirmed by b-actin western blot. Specific proteins were detected using the following primary antibodies: rabbit-anti-Mcl-1 (AAP-240, Stressgen, Ann Arbor, MI, USA), mouse-anti-p53 (AB-6 OP43, Calbiochem), rabbit-anti-Bcl-XL (sc-1041, Santa Cruz, Heidelberg, Germany), rabbit-anti-Bcl-2 (sc-492, Santa Cruz), rabbit-anti-Bax and rabbit-anti-Bak (ab32503 and ab32371, Abcam, Cambridge, UK), goatanti-Bid (AF680, R&D Systems, Minneapolis, MN, USA), rabbit-anti-Bim (#2819, Cell Signaling, Danvers, MA, USA), goat-anti-actin (sc-1615, Santa Cruz). Horseradish peroxidase-conjugated antibodies against mouse (AQ127P, Chemicon, Temecula, CA, USA), rabbit (7074,
Cell Signaling) or goat (sc-2056, Santa Cruz) were used as secondary antibodies. Proteins were visualized using the enhanced chemiluminescence detection system (ECL) according to the manufacturer's protocol (Amersham, Piscataway, NJ, USA).
Detection of apoptosis and cell killing
The induction of apoptosis was analyzed by Caspase-3 Activity Assay (Clontech). Briefly, cells were lysed in the assay buffer provided by the manufacturer, centrifuged and the supernatant was retained as cellular extract. Caspase-3 substrate (Ac-DEVD-AFC) with or without the caspase inhibitor, Ac-DEVD-CHO, was added and caspase-3 activity was measured using a fluorometer after 20 and 80 min. The measured fluorescence was normalized against protein concentration. Cytotoxicity was determined by trypan blue exclusion assay and flow cytometry analysis. Cells were treated in 6-cm wells and cultured for the indicated time. Detached cells were harvested by collecting supernatants; cells attached to the well were mildly detached by trypsinization. Suspensions were combined and subjected to trypan blue exclusion assay. Remaining cells were washed with FACS buffer and stained with propidium iodide immediately before FACS analysis.
Detection of autophagy
Induction of autophagy in YFP-LC3 transgenic cell lines was analyzed by western blot analysis (LC3-cleavage) using the mouse-anti rGFP (green fluorescent protein) as primary antibody (Becton-Dickinson, Heidelberg, Germany). In addition, intracellular YFP-LC3 distribution indicating the formation of autophagosomes was analyzed by fluorescence microscopy. For this purpose, cells were grown on cover glasses and exposed to virus or other agents, as indicated in the figure legends. At indicated time points, glasses were rinsed in PBS and fixed in 4% paraformaldehyde in PBS. The nucleus was stained with To-Pro3 (1 mM) and the glasses were mounted on microscopic slides using VectaShield (Vector Laboratories, Burlingame, CA , USA) mounting solution. The formation of autophagosomes was analyzed by confocal laser scanning microscopy (Zeiss LSM 510 Meta scan head on Zeiss Axiovert 200M equipped with an oil immersion objective lense Â 63/1.4, zoom factor 2.0; Carl Zeiss MicroImaging, Gö ttingen, Germany). Images were recorded and analyzed using Axiovision software (Carl Zeiss MicroImaging).
Animal experiments
Animal experiments were carried out in 6-8 week old pathogen-free NMRI nu/nu nude mice (from the Animal Research Institute of the MHH, Hannover, Germany) according to the German legal requirements (TierSchG). Tumors were inoculated by subcutaneous implantation of 1 Â 10 7 tumor cells into the flank of nude mice. Once subcutaneous tumors reached a mean size 250 ml, 1 Â 10 7 infectious particles of VSV in a volume of 150 ml were administered intratumorally. Treatment was repeated twice a week. 10 mg doxorubicin was applied intravenously in 300 ml PBS, in case of combination treatment, 6 h before VSV treatment. Tumor size was measured every 5 days using a digital caliper and tumor volume was calculated by using the equation V(tumor) ¼ (length Â width 2 )/2. Six animals per group were assessed.
Immunohistochemistry
For immunohistochemical analysis, tumor nodules were harvested, fixed in 4% paraformaldehyde in PBS and embedded in paraffin. Sections were then subjected to hematoxylin/eosin staining according to standard procedures. To visualize VSV-infected cells, slices were stained with rabbit-anti VSV-G antibody (V4888, Sigma), biotinylated donkey-anti-goat antibody (The Jackson Laboratories, Bar Harbor, ME, USA, 1:200) and streptavidine-horseradish peroxidase using the AEC Histostain Plus Broad Spectrum Kit (Zymed Laboratories, San Francisco, CA, USA). Analysis of apoptosis in vivo was carried out by TUNEL staining using the In Situ Cell Death Detection Kit, POD (Roche, Mannheim, Germany). Nuclei were counterstained by DAPI (4'-6-diamidino-2-phenylindole) (1 mg ml
À1
). TUNEL and DAPI-images were merged using Leica QWinV3 software.
RNAi-mediated gene silencing
For RNAi-mediated gene silencing, the vector pBS-U6 (kindly provided by Norman Woller) was used for introduction of hairpin RNA motives under control of a U6 promoter. DNA fragments encoding short hairpin RNA and Mir30 flanking sequences were generated by two-step PCR (primer details can be given upon request), termini were digested with Xba I and Xho I, and inserted downstream of the U6-promoter into the Sal I/Xba I sites of pBS-U6. Target sequences were CGGAACTGATCAG AACCATCAT (directed against human Bax) and GCCAGTTTGTGGTACGAAGAT (against human Bak). For the construction of lentiviral expression vectors, U6 promoter-dependent short hairpin RNA cassettes directed against Bak or Bax, or against tandems of both were excised by BamH I and Xba I, and introduced into the corresponding sites of a pLVTHM (Tronolab, Lausanne, Switzerland) that had been slightly modified before. These modifications included H1 promoter and Tetoperon excision between BamH I and Cla I, and replacement of green fluorescent protein by the neomycin resistance gene from pQCXIN. Lentiviral particles were generated by transfection of 293T packaging cells, and after 48 h incubation, the supernatant was concentrated by ultracentrifugation. Target cells were infected for 15 h and then selected with Neomycin. Successful knockdown was confirmed by western blot analysis.
Statistical analysis
Unpaired, two-tailed t-test (Mann-Whitney) was carried out using GraphPad Prism V3.02 software with Po0.05 accepted as denoting statistical significance.
